Preferred Label : Atibuclimab;
NCIt definition : A recombinant chimeric monoclonal antibody against human CD14, with potential anti-inflammatory
and immunomodulating activities. Upon administration, atibuclimab binds to and neutralizes
CD14, and prevents the interactions of CD14 with pathogen-associated molecular patterns
(PAMPs) and damage-associated molecular patterns (DAMPs) resulting from bacterial
and viral infection. This prevents membrane and soluble CD14-mediated signaling and
inflammatory cascade, and prevents cytokine release, granulocyte activation, and the
resulting tissue and organ injury. CD14, a protein involved in the innate recognition
of many pathogens including bacteria and viruses, is expressed on the surface of monocytes
and neutrophils and present in the blood and lung fluids as a soluble isoform. This
allows CD14 to amplify inflammatory responses in multiple sites in the body which
help fight infections, however, it may sometimes lead to overreaction and tissue and
organ injury.;
UNII : 23IQ3PO968;
CAS number : 336620-52-1;
Molecule name : IC-14; IC 14;
NCI Metathesaurus CUI : CL1406551;
Origin ID : C172657;
UMLS CUI : C5439903;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
